Physician profile
Anthony Pucillo
NPI 1619970530
$4,484.81
in general payments reported to CMS, 2019-2025
24 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,471 · 2020: $989 · 2022: $44.45 · 2023: $201 · 2024: $553 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832 · Entertainment: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.34 |
| Entertainment | $148.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $1,205.64 | 2019-2020 | |
| Cardiovascular Systems INC. | $975.29 | 2019-2020 | |
| Cardiva Medical, INC. | $873.40 | 2019-2024 | Other |
| Boston Scientific Corporation | $293.46 | 2019-2024 | Ranger, Eluvia |
| Opsens INC. | $148.25 | 2023 | Optowire |
| Abbott Laboratories | $142.38 | 2019 | |
| Abiomed | $141.93 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.07 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.24 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $92.03 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $78.92 | 2020-2024 | Venovo |
| E.R. Squibb & Sons, L.L.C. | $61.93 | 2019-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $36.73 | 2022-2025 | Farxiga |
| Shockwave Medical, INC | $35.83 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $28.93 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28.62 | 2019 | |
| Davol INC. | $28.07 | 2025 | Venovo |
| Portola Pharmaceuticals, LLC | $23.77 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.49 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.72 | 2023 | Xifaxan |
| Cook Medical LLC | $14.11 | 2025 | Zilver Vena |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Pucillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.